Biphasic response to human galanin of extracellular acidification in human Bowes melanoma cells.
The metabolic response of galanin GAL1 receptor subtype, endogenously expressed in human Bowes melanoma (HBM) cells, was investigated. Cytosensor microphysiometry was used to determine the extracellular acidification rate. A biphasic response, consisting of a rapid increase in the extracellular acidification rate followed by a decrease below the basal level, was observed after perfusion with human galanin. The magnitude and the rate of onset of both phases were dependent on the galanin concentration. The increase in the extracellular acidification rate (maximum of 25% of basal level; -log(EC(50))=7.23+/-0.14) was transient, whereas the following decrease (maximum of 40% of basal level; -log(EC(50))=7.77+/-0.23) was sustained. The EC(50) values for the increase and decrease were in a similar range. After consecutive galanin administration, the magnitude of the response was the same as for the unexposed cells, indicating the absence of galanin receptor desensitization or internalization in HBM cells. Responses were blocked by pretreatment with pertussis toxin and phorbol-12-myristate-13-acetate (PMA), indicating a G-protein/protein kinase C signalling pathway. Our microphysiometry results show a biphasic response of the extracellular acidification rate mediated by the galanin receptor expressed in HBM cells which has not been described previously for any other endogenously expressed neuropeptide receptor.
Lang
R
R
Department of Molecular Neurobiology and Cellular Physiology, Institute of Zoology, University of Salzburg, Hellbrunnerstrasse 34, A-5020 Salzburg, Austria.
Berger
A
A
Hermann
A
A
Kofler
B
B
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000143:Acids / Q000378:metabolism*; D000584:Amiloride / Q000494:pharmacology; D002460:Cell Line; D005576:Colforsin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005110:Extracellular Space / Q000187:drug effects / Q000378:metabolism; D019004:Galanin / Q000737:chemistry / Q000494:pharmacology*; D015870:Gene Expression; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008545:Melanoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D010446:Peptide Fragments / Q000494:pharmacology; D037342:Pertussis Toxin; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D044088:Receptors, Galanin; D018013:Receptors, Neuropeptide / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D013997:Time Factors; D014407:Tumor Cells, Cultured; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
D000143:Acids; D010446:Peptide Fragments; D012333:RNA, Messenger; D044088:Receptors, Galanin; D018013:Receptors, Neuropeptide; D010566:Virulence Factors, Bordetella; C062019:galanin (1-16); D005576:Colforsin; D000584:Amiloride; D019004:Galanin; D037342:Pertussis Toxin; D013755:Tetradecanoylphorbol Acetate; D015056:1-Methyl-3-isobutylxanthine